The UCLA ILD research program is a collaborative effort among patients, providers and scientists. The program has several types of interstitial lung disease research:
Patients may be asked if they are interested in participating in a research study. Participation is voluntary. The choice of whether or not to participate in a research study will not impact patient care in any way. Research funding comes from a variety of public and private sources.
To become involved in a research study
Speak with the physicians in the UCLA Interstitial Lung Disease Center about potential research studies. For additional information, call the coordinators for the ILD Research Program at (310) 794-2466.
Combining the anti-fibrotic effects of pirfenidone (PFD) with mycophenolate (MMF) for treating scleroderma-related interstitial lung disease.
Prospective Outcomes Registry of Subjects with Idiopathic Pulmonary Fibrosis. This registry will collect data on the strategies used to achieve a diagnosis of idiopathic pulmonary fibrosis (IPF) and the treatment and management efforts applied throughout study follow-up, clinical outcome events and patient-reported outcome data. Blood samples will be collected periodically throughout the study for use in future research efforts.
Pulmonary Fibrosis Foundation Patient Registry
This is a nationwide patient registry and biorepository for patients with pulmonary fibrosis. It is a collection of information about PF patients, including their diagnosis and how it was made, lab and test results, medications taken, and medical outcomes such as hospitalization, lung transplantation, and death. Participants are also asked to answer questions about their health, PF symptoms, and how they impact their lives. Participants may choose to contribute, at the time they enroll, blood samples to a biorepository that will store them for use in future research. When combined with the information in the Registry, these samples will help scientists find new causes of PF, identify means of determining whether treatments are working, improve the ways doctors manage the disease, and help discover new treatments.
This is a Phase 4, multicenter, randomized, double-blind, placebo-controlled pilot study evaluating the efficacy and safety of Acthar gel in the treatment of pulmonary sarcoidosis.
Novartis VAY736 IPF
The purpose of this study is to investigate the safety, tolerability and efficacy of VAY736, administered subcutaneously every 4 weeks for 48 weeks, as potential therapy for the treatment of idiopathic pulmonary fibrosis (IPF).
BI 11.99234 Pulmonary Rehabilitation
Study of pulmonary rehabilitation in nintedanib treated patients with idiopathic pulmonary fibrosis (IPF) to determine improvements in activity, exercise endurance and time and quality of life.
This is a Phase 2, double-blind placebo-controlled, randomized, multicenter, international study of 2 doses of ND-L02-s0201 for Injection to evaluate safety, tolerability, biological activity, and PK in subjects with a diagnosis of IPF with forced vital capacity (FVC) > 45% of predicted and diffusion capacity of the lung for carbon monoxide (DLco) > 30% of predicted and who meet all inclusion criteria and do not meet any exclusion criteria.
A phase 3, randomized, double-blind, parallel-group, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG 1690 in addition to local standard of care for minimum 52 weeks n subjects with idiopathic pulmonary fibrosis (IPF).
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of BG00011 in patients with idiopathic pulmonary fibrosis (IPF).
A double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with progressive fibrosing interstitial lung disease (PF-ILD). The aim of the current study is to investigate the efficacy and safety of nintedanib over 52 weeks in patients with progressive fibrosing interstitial lung disease (PF-ILD) defined as patients who present with features of diffuse fibrosing lung disease of >10% extent on high-resolution computed tomography (HRCT) and whose lung function and respiratory symptoms or chest imaging have worsened despite treatment with unapproved medications used in clinical practice to treat ILD. There is currently no efficacious treatment available for PF-ILD. Based on its efficacy and safety in idiopathic pulmonary fibrosis (IPF), it is anticipated that nintedanib will be a new treatment option for patients with PF-ILD.
A double-blind, randomized, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with systemic sclerosis-associated interstitial lung disease (SSC-ILD).
Abituzumab in SSc-ILD
The purpose of this trial is to compare two doses of abituzumab with placebo and determine whether abituzumab is more effective, safer, will be better tolerated and can provoke better immune response than placebo in the treatment of patients with SSc-ILD who already receive constant doses of mycophenolate.